Display options
Cite
Rhein J, Bahr NC, Morawski BM, et al. Detection of High Cerebrospinal Fluid Levels of (1→3)-β-d-Glucan in Cryptococcal Meningitis. Open Forum Infect Dis. 2014;1(3):ofu105doi: 10.1093/ofid/ofu105.
Rhein, J., Bahr, N. C., Morawski, B. M., Schutz, C., Zhang, Y., Finkelman, M., Meya, D. B., Meintjes, G., & Boulware, D. R. (2014). Detection of High Cerebrospinal Fluid Levels of (1→3)-β-d-Glucan in Cryptococcal Meningitis. Open forum infectious diseases, 1(3), ofu105. https://doi.org/10.1093/ofid/ofu105
Rhein, Joshua, et al. "Detection of High Cerebrospinal Fluid Levels of (1→3)-β-d-Glucan in Cryptococcal Meningitis." Open forum infectious diseases vol. 1,3 (2014): ofu105. doi: https://doi.org/10.1093/ofid/ofu105
Rhein J, Bahr NC, Morawski BM, Schutz C, Zhang Y, Finkelman M, Meya DB, Meintjes G, Boulware DR. Detection of High Cerebrospinal Fluid Levels of (1→3)-β-d-Glucan in Cryptococcal Meningitis. Open Forum Infect Dis. 2014 Nov 26;1(3):ofu105. doi: 10.1093/ofid/ofu105. eCollection 2014 Dec. PMID: 25734173; PMCID: PMC4324234.
Copy Download .nbib Format: NLM
Share it on

Open Forum Infect Dis. 2014 Nov 26;1(3):ofu105. doi: 10.1093/ofid/ofu105. eCollection 2014 Dec.

Detection of High Cerebrospinal Fluid Levels of (1→3)-β-d-Glucan in Cryptococcal Meningitis.

Open forum infectious diseases

Joshua Rhein, Nathan C Bahr, Bozena M Morawski, Charlotte Schutz, Yonglong Zhang, Malcolm Finkelman, David B Meya, Graeme Meintjes, David R Boulware

Affiliations

  1. University of Minnesota , Minneapolis ; Infectious Disease Institute , Makerere University , Kampala , Uganda.
  2. University of Minnesota , Minneapolis.
  3. University of Cape Town , South Africa.
  4. Associates of Cape Cod, Inc. , East Falmouth, Massachusetts.
  5. University of Cape Town , South Africa ; Imperial College London , United Kingdom.

PMID: 25734173 PMCID: PMC4324234 DOI: 10.1093/ofid/ofu105

Abstract

BACKGROUND: (1→3)-β-d-Glucan (BDG) is a helpful diagnostic marker for many invasive fungal infections. However, BDG is not thought to be useful in diagnosing cryptococcosis. We evaluated the utility of BDG as an adjunct diagnostic tool for patients infected with human immunodeficiency virus (HIV) and presenting with suspected cryptococcal meningitis.

METHODS: The Fungitell assay was used to measure BDG concentrations in cerebrospinal fluid (CSF) (n = 177) and serum (n = 109) of HIV-infected Ugandans and South Africans with suspected meningitis. Correlations between BDG concentrations and quantitative CSF cryptococcal cultures, CSF cryptococcal antigen (CRAG) titers, and 18 different CSF cytokine concentrations were assessed using non-parametric tests. Mixed models evaluated longitudinal changes in CSF BDG concentrations. Survival analyses were used to evaluate BDG's relationship with mortality.

RESULTS: The Fungitell BDG assay provided 89% sensitivity and 85% specificity in CSF for cryptococcal meningitis. Serum sensitivity was suboptimal (79%). Cerebrospinal fluid BDG concentrations at diagnosis were median (interquartile range) 343 (200-597) pg/mL in cryptococcal patients and 37 (23-46) pg/mL in patients without cryptococcosis. Sensitivity in CSF improved to 98% (53 of 54) when initial fungal burdens were ≥10 000 colony-forming units/mL. (1→3)-β-d-Glucan normalized rapidly after initiating antifungal therapy. Baseline BDG concentrations correlated with CSF fungal burden (rho = 0.820; P < .001), CSF CRAG lateral flow assay titers (rho = 0.780, P < .001), and monocyte chemotactic protein-1 levels in CSF (P = .047). In patients with cryptococcal meningitis, BDG ≥500 pg/mL at diagnosis was associated with increased 10-week mortality.

CONCLUSIONS: (1→3)-β-d-Glucan is detectable in the CSF of HIV-infected patients with Cryptococcus, and it may provide useful prognostic information. Sensitivity is less than CRAG; however, BDG normalizes rapidly, unlike CRAG, making BDG potentially useful in diagnosing recurrent episodes.

Keywords: AIDS; HIV; cryptococcal meningitis; predictive value of tests; β-glucan

References

  1. J Infect Dis. 2009 Jun 1;199(11):1664-70 - PubMed
  2. Clin Infect Dis. 2008 Jun 15;46(12):1813-21 - PubMed
  3. J Infect Dis. 2000 Feb;181(2):791-4 - PubMed
  4. J Clin Microbiol. 2010 Nov;48(11):4083-8 - PubMed
  5. Lancet. 2004 May 29;363(9423):1764-7 - PubMed
  6. J Microbiol Immunol Infect. 2011 Oct;44(5):338-45 - PubMed
  7. MBio. 2012 Sep 25;3(5):null - PubMed
  8. Med Mycol. 2006 May;44(3):267-72 - PubMed
  9. Clin Infect Dis. 2014 Mar;58(5):622-30 - PubMed
  10. J Immunol. 2005 Feb 1;174(3):1746-50 - PubMed
  11. Clin Infect Dis. 2008 Jun 15;46(12):1930-1 - PubMed
  12. Clin Infect Dis. 1994 May;18(5):789-92 - PubMed
  13. Lancet. 1995 Jan 7;345(8941):17-20 - PubMed
  14. Clin Infect Dis. 2014 Mar;58(5):736-45 - PubMed
  15. J AIDS Clin Res. 2013 Apr 29;Suppl 3(3):null - PubMed
  16. J Leukoc Biol. 2000 Dec;68(6):923-32 - PubMed
  17. J Clin Microbiol. 1996 Aug;34(8):1918-21 - PubMed
  18. N Engl J Med. 2006 Jun 29;354(26):2834-5 - PubMed
  19. Infect Immun. 1988 Apr;56(4):849-54 - PubMed
  20. Lancet Infect Dis. 2010 Nov;10(11):791-802 - PubMed
  21. APMIS. 2011 Apr;119(4-5):280-6 - PubMed
  22. N Engl J Med. 2014 Jun 26;370(26):2487-98 - PubMed
  23. Infection. 2007 Oct;35(5):346-51 - PubMed
  24. Int J Surg Pathol. 2009 Dec;17(6):444-8 - PubMed
  25. Ann N Y Acad Sci. 2008 Nov;1143:45-60 - PubMed
  26. Antimicrob Agents Chemother. 2008 Nov;52(11):4121-9 - PubMed
  27. Clin Infect Dis. 2014 Jan;58(1):113-6 - PubMed
  28. Clin Infect Dis. 2008 Jun 15;46(12):1864-70 - PubMed
  29. Clin Infect Dis. 2005 Sep 1;41(5):654-9 - PubMed
  30. Emerg Infect Dis. 2014 Jan;20(1):45-53 - PubMed
  31. Int J Clin Lab Res. 1997;27(2):118-22 - PubMed
  32. J Clin Microbiol. 1995 Dec;33(12):3115-8 - PubMed
  33. Clin Infect Dis. 2007 Jul 1;45(1):76-80 - PubMed
  34. J Clin Microbiol. 2014 Jun;52(6):1921-31 - PubMed
  35. Clin Infect Dis. 2013 May;56(10):1511-2 - PubMed

Publication Types

Grant support